Skip to main content
SpringerLink
Log in

Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori

  • Review
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Helicobacter pylori (H. pylori) is one of the leading causes of gastric diseases such as chronic gastritis, peptic ulcer, and gastric adenocarcinoma. The current treatment of H. pylori infection with antibiotics and proton pump inhibitors has several limitations, including poor adherence and intrinsic patient-related factors, drug resistance, and the absence of adequate treatments. This review summarizes the current therapeutic approaches to eradicating H. pylori, the difficulties associated with its treatment, and several new perspectives aimed at improving existing treatment strategies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002;347:1175–1186.

    Article  CAS  PubMed  Google Scholar 

  2. Ayala G, Escobedo-Hinojosa WI, Cruz-Herrera CF, Romero I. Exploring alternative treatments for Helicobacter pylori infection. World J Gastroenterol. 2014;20:1450–1469.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Gustafson J, Welling D. “No acid, no ulcer”—100 years later: a review of the history of peptic ulcer disease. Am Coll Surg. 2010;210:110–116.

    Article  Google Scholar 

  4. Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet. 1983;1:1273–1275.

    Google Scholar 

  5. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. JAMA. 1995;272:65–69.

    Google Scholar 

  6. Garza-González E, Perez-Perez GI, Maldonado-Garza HJ, Bosques-Padilla FJ. A review of Helicobacter pylori diagnosis, treatment, and methods to detect eradication. World J Gastroenterol. 2014;20:1438–1449.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  7. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci. 2014;59:1698–1709.

    Article  PubMed  Google Scholar 

  8. Hunt RH, Xiao SD, Megraud F, et al. World Gastroenterology Organization. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;20:299–304.

    CAS  PubMed  Google Scholar 

  9. Alarcón T, Martínez-Gomez MJ, Urruzuno P. Helicobacter pylori in pediatrics. Helicobacter. 2013;18:52–57.

    Article  PubMed  Google Scholar 

  10. Lehours P, Yilmaz O. Epidemiology of Helicobacter pylori infection. Helicobacter. 2007;12:1–3.

    Article  PubMed  Google Scholar 

  11. Egan BJ, Katicic M, O’Connor HJ, O’Morain CA. Treatment of Helicobacter pylori. Helicobacter. 2007;12:31–37.

    Article  CAS  PubMed  Google Scholar 

  12. Gerrits MM, Van Vliet AH, Kuipers EJ, Kusters JG. Helicobacter pylori and antimicrobial resistance: molecular mechanisms and clinical implications. Lancet Infect Dis. 2006;6:699–709.

    Article  CAS  PubMed  Google Scholar 

  13. Boltin D, Ben-Zvi H, Perets TT, et al. Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned? J Clin Microbiol. 2015;53:522–527.

    Article  PubMed Central  PubMed  Google Scholar 

  14. Shiota S, Reddy R, Alsarraj A, El-Serag HB, Graham DY. Antibiotic resistance of Helicobacter pylori among male US veterans. Clin Gastroenterol Hepatol. 2015;S1542–3565:00122–00126.

    Google Scholar 

  15. Pacifico L, Osborn JF, Bonci E, Romaggioli S, Baldini R, Chiesa C. Probiotics for the treatment of Helicobacter pylori infection in children. World J Gastroenterol. 2014;20:673–683.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Kamiji MM, de Oliveira RB. Non-antibiotic therapies for Helicobacter pylori infection. Eur J Gastroenterol Hepatol. 2005;17:973–981.

    Article  CAS  PubMed  Google Scholar 

  17. Kusters JG, Van Vliet AH, Kuipers EJ. Pathogenesis of Helicobacter pylori infection. Clin Microbiol Rev. 2006;19:449–490.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Blaser MJ. Who are we? Indigenous microbes and the ecology of human diseases. EMBO Rep. 2006;7:956–960.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  19. Maeda S, Mentis AF. Pathogenesis of Helicobacter pylori infection. Helicobacter. 2007;1:10–14.

    Article  Google Scholar 

  20. Kalali B, Mejías-Luque R, Javaheri A, Gerhard MH. pylori virulence factors: influence on immune system and pathology. Mediators Inflamm. 2014;2014:426309.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  21. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther. 2007;26:343–357.

    Article  CAS  PubMed  Google Scholar 

  22. Malfertheiner P, Megraud F, O’morain CA, et al. Management of Helicobacter pylori infection—the Maastricht IV/Florence consensus report. Gut. 2012;61:646–664.

    Article  CAS  PubMed  Google Scholar 

  23. De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis. 2004;36:322–326.

    Article  PubMed  Google Scholar 

  24. Zullo A, Gatta L, De Francesco V, et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther. 2005;21:1419–1424.

    Article  CAS  PubMed  Google Scholar 

  25. Scaccianoce G, Hassan C, Panarese A, Piglionica D, Morini S, Zullo A. Helicobacter pylori eradication with either 7-day or 10-day triple therapies, and with a 10-day sequential regimen. Can J Gastroenterol. 2006;20:113–117.

    PubMed Central  PubMed  Google Scholar 

  26. Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med. 2007;146:556–563.

    Article  PubMed  Google Scholar 

  27. O’Connor A, Molina-Infante J, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter. 2013;18:58–65.

    Article  PubMed  Google Scholar 

  28. Zhou L, Zhang J, Chen M, et al. A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial. Am J Gastroenterol. 2014;109:535–541.

    Article  CAS  PubMed  Google Scholar 

  29. Liu KS, Hung IF, Seto WK, et al. Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical first line and second line treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial. Gut. 2013;63:1410–1415.

    Article  PubMed  CAS  Google Scholar 

  30. Mcnicholl AG, Marin AC, Molina-Infante J, et al. Participant Centres. Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice. Gut. 2014;63:244–249.

    PubMed  Google Scholar 

  31. Molina-Infante J, Romano M, Fernandez-Bermejo M, et al. Optimized nonbismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance. Gastroenterology. 2013;145:121–128.

    Article  CAS  PubMed  Google Scholar 

  32. Zullo A, Scaccianoce G, De Francesco V, et al. Concomitant, sequential, and hybrid therapy for H. pylori eradication: a pilot study. Clin Res Hepatol Gastroenterol. 2013;37:647–650.

    Article  CAS  PubMed  Google Scholar 

  33. Yang JC, Lin CJ, Wang HL, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13:895–905.e5.

    Article  CAS  PubMed  Google Scholar 

  34. Marin AC, Mcnicholl AG, Gisbert JP. A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). Expert Opin Pharmacother. 2013;14:843–861.

    Article  CAS  PubMed  Google Scholar 

  35. Gisbert JP, Castro-Fernandez M, Perez-Aisa A, et al. Fourth-line rescue therapy with rifabutin in patients with three Helicobacter pylori eradication failures. Aliment Pharmacol Ther. 2012;35:941–947.

    Article  CAS  PubMed  Google Scholar 

  36. Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol. 2014;20:1517–1528.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  37. Di Caro S, Fini L, Daoud Y, et al. Levofloxacin/amoxicillin-based schemes vs quadruple therapy for Helicobacter pylori eradication in second-line. World J Gastroenterol. 2012;18:5669–5678.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  38. Gisbert JP, Molina-Infante J, Ac Marin, et al. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple “sequential” or “concomitant” treatment to eradicate H. pylori infection. Scand J Gastroenterol. 2013;48:652–656.

    Article  CAS  PubMed  Google Scholar 

  39. Wu C, Chen X, Liu J, Li MY, Zhang ZQ, Wang ZQ. Moxifloxacin-containing triple therapy versus bismuth-containing quadruple therapy for second-line treatment of Helicobacter pylori infection: a meta-analysis. Helicobacter. 2011;16:131–138.

    Article  CAS  PubMed  Google Scholar 

  40. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011;16:420–426.

    Article  CAS  PubMed  Google Scholar 

  41. Matsumoto Y, Miki I, Aoyama N, et al. Levofloxacin versus metronidazole-based rescue therapy for H. pylori infection in Japan. Dig Liver Dis. 2005;37:821–825.

    Article  CAS  PubMed  Google Scholar 

  42. Morgan DR, Torres J, Sexton R, et al. Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. JAMA. 2013;309:578–586.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  43. González Carro P, Pérez Roldán F, De Pedro Esteban A, et al. Efficacy of rifabutin-based triple therapy in Helicobacter pylori infected patients after two standard treatments. J Gastroenterol Hepatol. 2007;22:60–63.

    Article  PubMed  CAS  Google Scholar 

  44. Fiorini G, Vakil N, Zullo A, et al. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2013;11:507–510.

    Article  CAS  PubMed  Google Scholar 

  45. Gisbert JP, Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther. 2012;35:209–221.

    Article  CAS  PubMed  Google Scholar 

  46. Gasbarrini A, Gasbarrini G, Pelosini I, Scarpignato C. Eradication of Helicobacter pylori: are rifaximin-based regimens effective? Digestion. 2006;73:129–135.

    Article  CAS  PubMed  Google Scholar 

  47. Gasbarrini A, Lauritano EC, Nista EC, et al. Rifaximin-based regimens for eradication of Helicobacter pylori: a pilot study. Dig Dis. 2006;24:195–200.

    Article  PubMed  Google Scholar 

  48. Yun SP, Seon HG, Ok CS, et al. Rifaximin plus levofloxacin-based rescue regimen for the eradication of Helicobacter pylori. Gut Liver. 2012;6:452–456.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  49. Hunt Rh, Xiao SD, Megraud F, et al. Helicobacter pylori in developing countries. World Gastroenterology Organisation Global Guideline. J Gastrointestin Liver Dis. 2011;2:299–304.

    Google Scholar 

  50. Tursi A, Picchio M, Elisei W. Efficacy and tolerability of a third-line, levofloxacin-based, 10-day sequential therapy in curing resistant Helicobacter pylori infection. J Gastrointestin Liver Dis. 2012;21:133–138.

    PubMed  Google Scholar 

  51. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis. 2003;35:232–236.

    Article  CAS  PubMed  Google Scholar 

  52. Matsuzaki J, Suzuki H, Nishizawa T, et al. Efficacy of sitafloxacin based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies. Antimicrob Agents Chemother. 2012;56:1643–1645.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  53. Hirata Y, Ohmae T, Yanai A, et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents. 2012;39:352–355.

    Article  CAS  PubMed  Google Scholar 

  54. Murakami K, Furuta T, Ando T, et al. Japan Gast Study Group. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013;48:1128–1135.

    Article  PubMed  Google Scholar 

  55. Alsahli M, Michetti P. Lactobacilli for the management of Helicobacter pylori. Nutrition. 2001;17:268–269.

    Article  CAS  PubMed  Google Scholar 

  56. Midolo PD, Lambert JR, Hull R, Luo F, Grayson ML. In vitro inhibition of Helicobacter pylori NCTC 11637 by organic acids and lactic acid bacteria. J Appl Bacteriol. 1995;79:475–479.

    Article  CAS  PubMed  Google Scholar 

  57. Guruge JL, Falk PG, Lorenz RG, et al. Epithelial attachment alters the outcome of Helicobacter pylori infection. Proc Natl Acad Sci USA. 1998;95:3925–3930.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  58. Byrd JC, Yunker CK, Xu QS, Sternberg LR, Bresalier RS. Inhibition of gastric mucin synthesis by Helicobacter pylori. Gastroenterol. 2000;118:1072–1079.

    Article  CAS  Google Scholar 

  59. Mukai T, Asasaka T, Sato E, Mori K, Matsumoto M, Ohori H. Inhibition of binding of Helicobacter pylori to the glycolipid receptors by probiotic Lactobacillus reuteri. FEMS Immunol Med Microbiol. 2002;2:105–110.

    Article  Google Scholar 

  60. Haller D, Bode C, Hammes WP, Pfeifer AM, Schiffrin EJ, Blum S. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79–87.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  61. Gill HS. Probiotics to enhance anti-infective defences in the gastrointestinal tract. Best Pract Res Clin Gastroenterol. 2003;17:755–773.

    Article  CAS  PubMed  Google Scholar 

  62. Goldman CG, Barrado DA, Balcarce N, et al. Effect of a probiotic food as an adjuvant to triple therapy for eradication of Helicobacter pylori infection in children. Nutrition. 2006;22:984–988.

    Article  PubMed  Google Scholar 

  63. Szajewska H, Albrecht P, Topczewska-Cabanek A. Randomized, double-blind, placebo-controlled trial: effect of lactobacillus GG supplementation on Helicobacter pylori eradication rates and side effects during treatment in children. J Pediatr Gastroenterol Nutr. 2009;48:431–436.

    Article  CAS  PubMed  Google Scholar 

  64. Lv Z, Wang B, Zhou X, et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9:707–716.

    PubMed Central  CAS  PubMed  Google Scholar 

  65. Dang Y, Reinhardt JD, Zhou X, Zhang G. The effect of probiotics supplementation on Helicobacter pylori eradication rates and side effects during eradication therapy: a meta-analysis. PLoS ONE. 2014;9:e111030.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  66. Wang ZH, Gao QY, Fang JY. Meta-analysis of the efficacy and safety of Lactobacillus containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47:25–32.

    Article  PubMed  Google Scholar 

  67. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–1079.

    Article  CAS  PubMed  Google Scholar 

  68. Li S, Huang XL, Sui JZ, et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173:153–161.

    Article  PubMed  Google Scholar 

  69. Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter. 2013;18:18–23.

    Article  PubMed  Google Scholar 

  70. Kanizaj TF, Kunac N. Helicobacter pylori: future perspectives in therapy reflecting three decades of experience. World J Gastroenterol. 2014;20:699–705.

    Article  PubMed Central  PubMed  Google Scholar 

  71. Malfertheiner P, Selgrad M, Wex T. Efficacy of an investigational recombinant antigen based vaccine against a CagA H. pylori infectious challenge in healthy volunteers. Gastroenterology. 2012;142:S-184.

    Article  Google Scholar 

  72. Koch M, Meyer TF, Moss SF. Inflammation, immunity, vaccines for Helicobacter pylori infection. Helicobacter. 2013;18:18–23.

    Article  PubMed  Google Scholar 

  73. Chen J, Lin M, Li N, Lin L, She F. Therapeutic vaccination with Salmonella-delivered codon-optimized outer inflammatory protein DNA vaccine enhances protection in Helicobacter pylori infected mice. Vaccine. 2012;30:5310–5315.

    Article  CAS  PubMed  Google Scholar 

  74. Altman E, Chandan V, Harrison BA, et al. Regional Helicobacter Pylori Study Group. Design and immunological properties of Helicobacter pylori glycoconjugates based on a truncated lipopolysaccharide lacking Lewis antigen and comprising an alpha-1,6-glucan chain. Vaccine. 2012;30:7332–7341.

    Article  CAS  PubMed  Google Scholar 

  75. Li Y, Jiang Y, Xi Y, et al. Identification and characterization of H-2d restricted CD4+ T cell epitopes on Lpp 20 of Helicobacter pylori. BMC Immunol. 2012;13:68.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  76. Li HB, Zhang JY, He YF, et al. Systemic immunization with an epitope-based vaccine elicits a Th1-biased response and provides protection against Helicobacter pylori in mice. Vaccine. 2012;31:120–126.

    Article  PubMed  CAS  Google Scholar 

  77. Yanaka A. Sulforaphane enhances protection and repair of gastric mucosa against oxidative stress in vitro, and demonstrates anti-inflammatory effects on Helicobacter pylori infected gastric mucosae in mice and human subjects. Curr Pharm Des. 2011;17:1532–1540.

    Article  CAS  PubMed  Google Scholar 

  78. Cerella C, Dicato M, Jacob C, Diederich M. Chemical properties and mechanisms determining the anti-cancer action of garlic-derived organic sulfur compounds. Anti-Cancer Agents Med Chem. 2011;1:267–271.

    Article  Google Scholar 

  79. Borkowska A, Knap N, Antosiewicz J. Diallyl trisulfide is more cytotoxic to prostate cancer cells PC-3 than to noncancerous epithelial cell line PNT1A: a possible role of p66Shc signaling axis. Nutr Cancer. 2013;65:711–717.

    Article  CAS  PubMed  Google Scholar 

  80. Schäfer G, Kaschula CH. The immunomodulation and anti-inflammatory effects of garlic organosulfur compounds in cancer chemoprevention. Anti-Cancer Agents Med Chem. 2014;14:233–240.

    Article  CAS  Google Scholar 

  81. Sivam GP, Lampe JW, Ulness B, Swanzy SR, Potter JD. Helicobacter pylori—in vitro susceptibility to garlic (Allium sativum) extract. Nutr Cancer. 1997;27:118–121.

    Article  CAS  PubMed  Google Scholar 

  82. Iimuro M, Shibata H, Kawamori T, et al. Suppressive effects of garlic extract on Helicobacter pylori-induced gastritis in Mongolian gerbils. Cancer Lett. 2002;187:61–68.

    Article  CAS  PubMed  Google Scholar 

  83. Graham DY, Anderson SY, Lang T. Garlic or jalapeño peppers for treatment of Helicobacter pylori infection. Am J Gastroenterol. 1999;94:1200–1202.

    CAS  PubMed  Google Scholar 

  84. McNulty CA, Wilson MP, Havinga W, Johnston B, O’Gara EA, Maslin DJ. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori. Helicobacter. 2001;6:249–253.

    Article  CAS  PubMed  Google Scholar 

  85. You WC, Brown LM, Zhang L, et al. Randomized double blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst. 2006;98:974–983.

    Article  PubMed  Google Scholar 

  86. Matsubara S, Shibata H, Ishikawa F, et al. Suppression of Helicobacter pylori-induced gastritis by green tea extract in Mongolian gerbils. Biochem Biophys Res Commun. 2003;310:715–719.

    Article  CAS  PubMed  Google Scholar 

  87. Tombola F, Campello S, De Luca L, et al. Plant polyphenols inhibit VacA, a toxin secreted by the gastric pathogen Helicobacter pylori. FEBS Lett. 2003;543:184–189.

    Article  CAS  PubMed  Google Scholar 

  88. Stoicov C, Saffari R, Houghton J. Green tea inhibits Helicobacter growth in vivo and in vitro. Int J Antimicrob Agents. 2009;33:473–478.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  89. Mabe K, Yamada M, Oguni I, Takahashi T. In vitro and in vivo activities of tea catechins against Helicobacter pylori. Antimicrob Agents Chemother. 1999;43:1788–1791.

    PubMed Central  CAS  PubMed  Google Scholar 

  90. Paulo L, Oleastro M, Gallardo E, Queiroz JA, Domingues F. Anti-Helicobacter pylori and urease inhibitory activities of resveratrol and red wine. Food Res Int. 2011;44:964–969.

    Article  CAS  Google Scholar 

  91. Asha MK, Debraj D, Prashanth D, et al. In vitro anti-Helicobacter pylori activity of a flavonoid rich extract of Glycyrrhiza glabra and its probable mechanisms of action. J Ethnopharmacol. 2013;145:581–586.

    Article  CAS  PubMed  Google Scholar 

  92. Kim JM, Zheng HM, Lee BY, Lee WK, Lee DH. Anti-Helicobacter pylori properties of gut gard. Prev Nutr Food Sci. 2013;18:104–110.

    Article  PubMed Central  PubMed  Google Scholar 

  93. Osato MS, Reddy SG, Graham DY. Osmotic effect of honey on growth and viability of Helicobacter pylori. Dig Dis Sci. 1999;44:462–464.

    Article  CAS  PubMed  Google Scholar 

  94. McGovern DP, Abbas SZ, Vivian G, Dalton HR. Manuka honey against Helicobacter pylori. J R Soc Med. 1999;92:439.

    PubMed Central  CAS  PubMed  Google Scholar 

  95. Cui K, Lu W, Zhu L, Shen X, Huang J. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits Helicobacter pylori peptide deformylase activity. Biochem Biophys Res Commun. 2013;435:289–294.

    Article  CAS  PubMed  Google Scholar 

  96. Coelho LG, Bastos EM, Resende CC, et al. Brazilian green propolis on Helicobacter pylori infection. A pilot clinical study. Helicobacter. 2007;12:572–574.

    Article  PubMed  Google Scholar 

  97. Santos AM, Lopes T, Oleastro M, et al. Curcumin inhibits gastric inflammation induced by Helicobacter pylori infection in a mouse model. Nutrients. 2015;7:306–320.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  98. De R, Kundu P, Swarnakar S, et al. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob Agents Chemother. 2009;53:1592–1597.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  99. Aditi A, Graham DY. Vitamin C, gastritis and gastric disease: a historical review and update. Dig Dis Sci. 2012;57:2504–2515.

    Article  CAS  PubMed  Google Scholar 

  100. Sezikli M, Çetinkaya ZA, Güzelbulut F, et al. Effects of alpha tocopherol and ascorbic acid on Helicobacter pylori colonization and the severity of gastric inflammation. Helicobacter. 2012;17:127–132.

    Article  CAS  PubMed  Google Scholar 

  101. Li G, Li L, Yu C, Chen L. Effect of vitamins C and E supplementation on Helicobacter pylori eradication: a meta-analysis. Br J Nutr. 2011;106:1632–1637.

    Article  CAS  PubMed  Google Scholar 

  102. Dekker KA, Inagaki T, Gootz TD, et al. CJ-12,954 and its congeners, new anti-Helicobacter pylori compounds produced by Phanerochaete velutina: fermentation, isolation, structural elucidation and biological activities. J Antibiot. 1997;50:833–839.

    Article  CAS  PubMed  Google Scholar 

  103. Kanamaru T, Nakano Y, Toyoda Y, et al. In vitro and in vivo antibacterial activities of TAK-083, an agent for treatment of Helicobacter pylori infection. Antimicrob Agents Chemother. 2001;45:2455–2459.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  104. Vecchione JJ, Sello JK. A novel tryptophanyl-tRNA synthetase gene confers high-level resistance to indolmycin. Antimicrob Agents Chemother. 2009;53:3972–3980.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  105. Lee JH, Shim JS, Lee JS, et al. Inhibition of pathogenic bacterial adhesion by acidic polysaccharide from green tea (Camellia sinensis). J Agric Food Chem. 2006;54:8717–8723.

    Article  CAS  PubMed  Google Scholar 

  106. Wittschier N, Faller G, Hensel A. Aqueous extracts and polysaccharides from liquorice roots (Glycyrrhiza glabra L.) inhibit adhesion of Helicobacter pylori to human gastric mucosa. J Ethnopharmacol. 2009;125:218–223.

    Article  CAS  PubMed  Google Scholar 

  107. Lengsfeld C, Deters A, Faller G, Hensel A. High molecular weight polysaccharides from black currant seeds inhibit adhesion of Helicobacter pylori to human gastric mucosa. Planta Med. 2004;70:620–626.

    Article  CAS  PubMed  Google Scholar 

  108. Loke MF, Lui SY, Ng BL, Gong M, Ho B. Antiadhesive property of microalgal polysaccharide extract on the binding of Helicobacter pylori to gastric mucin. FEMS Immunol Med Microbiol. 2007;50:231–238.

    Article  CAS  PubMed  Google Scholar 

  109. Funakoshi R, Yokoyama H, Kawai N, Kobayashi K, Ueno F, Yamada Y. Effect of pharmaceutical care in the diagnosis of Helicobacter pylori infection using 13C-urea breath test. Yakugaku Zasshi. 2012;132:601–607.

    Article  CAS  PubMed  Google Scholar 

  110. Lomas J, Anderson GM, Domnick-Pierre K, et al. Do practice guidelines guide practice? The effect of a consensus statement on the practice of physicians. N Engl J Med. 1989;321:1306–1311.

    Article  CAS  PubMed  Google Scholar 

  111. Erah PO, Goddard AF, Barrett DA, Shaw PN, Spiller RC. The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection. J Antimicrob Chemother. 1997;39:5–12.

    Article  CAS  PubMed  Google Scholar 

  112. Tang HL, Li Y, Hu YF, Xie HG, Zhai SD. Effects of CYP2C19 loss-of-function variants on the eradication of H. pylori infection in patients treated with proton pump inhibitor-based triple therapy regimens: a meta-analysis of randomized clinical trials. PLoS ONE. 2013;8:e62162.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  113. Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–528.

    Article  CAS  PubMed  Google Scholar 

  114. Rice PJ, Perry RJ, Afzal Z, Stockley IH. Antibacterial prescribing and warfarin: a review. Br Dent J. 2003;194:411–415.

    Article  CAS  PubMed  Google Scholar 

  115. Huynh T, Cordato D, Yang F, et al. HMG CoA reductase-inhibitor-related myopathy and the influence of drug interactions. Intern Med J. 2002;32:486–490.

    Article  CAS  PubMed  Google Scholar 

  116. Sahai J, Healy DP, Stotka J, Polk RE. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br J Clin Pharmacol. 1993;35:302–304.

    PubMed Central  CAS  PubMed  Google Scholar 

  117. Lu ZK, Yuan J, Li M, et al. Cardiac risks associated with antibiotics: azithromycin and levofloxacin. Expert Opin Drug Saf. 2015;14:295–303.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  118. Villamañán E, Armada E, Ruano M. Drug-induced QT interval prolongation: do we know the risks? Med Clin (Barc). 2015;144:269–274.

    Article  Google Scholar 

  119. Ericsson CD, Feldman S, Pickering LK, Cleary TG. Influence of subsalicylate bismuth on absorption of doxycycline. JAMA. 1982;247:2266–2267.

    Article  CAS  PubMed  Google Scholar 

  120. Boyanova L. Prevalence of multidrug-resistant Helicobacter pylori in Bulgaria. J Med Microbiol. 2009;58:930–935.

    Article  CAS  PubMed  Google Scholar 

  121. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: a matter of geography? World J Gastroenterol. 2013;19:8168–8180.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  122. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastroint Liver Dis. 2010;19:409–414.

    Google Scholar 

  123. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic Resistance. Gut. 2009;59:1143–1153.

    Article  CAS  Google Scholar 

  124. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009;24:1587–1600.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The authors are grateful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Coordenação de Aperfeiçoamento Pessoal de Ensino Superior (CAPES) for support of the study.

Conflict of interest

None.

Author information

Author notes

    Authors and Affiliations

    1. School of Pharmaceutical Science, Drugs and Medicines Department, State University of São Paulo “Júlio de Mesquita Filho”, Rodovia Araraquara Jaú Km, 01 s/n, Araraquara, SP, 14801-902, Brazil

      Priscila Baptistella Yazbek, Ariane Biolcati Trindade, Chung Man Chin & Jean Leandro dos Santos

    Authors
    1. Priscila Baptistella Yazbek
      View author publications

      You can also search for this author in PubMed Google Scholar

    2. Ariane Biolcati Trindade
      View author publications

      You can also search for this author in PubMed Google Scholar

    3. Chung Man Chin
      View author publications

      You can also search for this author in PubMed Google Scholar

    4. Jean Leandro dos Santos
      View author publications

      You can also search for this author in PubMed Google Scholar

    Corresponding author

    Correspondence to Jean Leandro dos Santos.

    Additional information

    All authors contributed equally to this work.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Yazbek, P.B., Trindade, A.B., Chin, C.M. et al. Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori . Dig Dis Sci 60, 2901–2912 (2015). https://doi.org/10.1007/s10620-015-3712-y

    Download citation

    • Received:

    • Accepted:

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s10620-015-3712-y

    Keywords

    Search

    Navigation